KRAS & NRAS StripAssay

Print
mutations in the KRAS and NRAS genes
Description

Monoclonal antibody therapies targeting EGFR work exceptionally well in metastatic colorectal cancer. However, certain mutations in the KRAS and NRAS genes prevent success of these therapies.

The KRAS and NRAS StripAssays rapidly the most relevant mutations in the KRAS and NRAS genes.

KRAS & NRAS Mutations

  • Epidermal Growth Factor (EGF) activates cell proliferation by binding to the EGF-Receptor (EGFR). This triggers a signal transduction pathway that includes the KRAS and NRAS proteins.
  • Inhibiting EGFR with monoclonal EGFR antibodies prevents activation of the relevant signal transduction pathway.
  • However, certain mutations in KRAS or NRAS result in permanent activation of parts of this pathway, rendering anti-EGFR therapies ineffective.
  • Identification of KRAS and NRAS mutations thus allows patient-specific treatment and prediction of tumor progression.

 

Download KRAS Brochure

Download NRAS Brochure

Cat. VL-5-590 - KRAS StripAssay (20 Tests) Pack Insert

Cat. VL-5-680 - KRAS XL StripAssay (20 Tests) Pack Insert

Cat. VL-5-690 - KRAS 12/13/61 StripAssay (20 Tests) Pack Insert

Cat. VL-5-610 - NRAS StripAssay (20 Tests) Pack Insert

Cat. VL-5-620 - NRAS XL StripAssay (20 Tests) Pack Insert

 

Literature

Reviews

There are yet no reviews for this product.

Company

Policies

Social

Back To Top

Back To Top

Disclaimer: The demo content provided with this template is for demo purposes only. All content (C) the original authors.